Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorFUKUZAKI, Silvia
dc.contributor.authorRIGHETTI, Renato Fraga
dc.contributor.authorSANTOS, Tabata Maruyama dos
dc.contributor.authorCAMARGO, Leandro do Nascimento
dc.contributor.authorARISTOTELES, Luciana R. C. R. B.
dc.contributor.authorSOUZA, Flavia C. R.
dc.contributor.authorGARRIDO, Aurelio C.
dc.contributor.authorSARAIVA-ROMANHOLO, Beatriz Mangueira
dc.contributor.authorLEICK, Edna Aparecida
dc.contributor.authorPRADO, Carla Maximo
dc.contributor.authorMARTINS, Milton de Arruda
dc.contributor.authorTIBERIO, Iolanda de Fatima Lopes Calvo
dc.identifier.citationAMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, v.320, n.3, p.C341-C354, 2021
dc.description.abstractChronic obstructive pulmonary disease (COPD) is an important health care issue, and IL-17 can modulate inflammatory responses. We evaluated preventive and therapeutic effect of anti-interleukin (IL)-17 in a model of lung injury induced by elastase, using 32 male C57Bl6 mice, divided into 4 groups: SAL, ELASTASE CONTROL (EC), ELASTASE I PREVENTIVE ANTI-IL-17 (EP), and ELASTASE + THERAPEUTIC ANTI-IL-17 (ET). On the 29th day, animals were anesthetized with thiopental, tracheotomized, and placed on a ventilator to evaluate lung mechanical, exhaled nitric oxide (eNO), and total cells of bronchoalveolar lavage fluid was collected. We performed histological techniques, and linear mean intercept (Lm) was analyzed. Both treatments with anti-IL-17 decreased respiratory resistance and elastance, airway resistance, elastance of pulmonary parenchyma, eNO, and Lm compared with EC. There was reduction in total cells and macrophages in ET compared with EC. Both treatments decreased nuclear factor-kappa B, inducible nitric oxide synthase, matrix metalloproteinase (MMP)-9, MMP-12, transforming growth factor-beta, tumor necrosis factor-alpha, neutrophils, IL-1 beta, isoprostane, and IL-17 in airways and alveolar septa; collagen fibers, decorin and lumican in airways; and elastic fibers and fibronectin in alveolar septa compared with EC. There was reduction of collagen fibers in alveolar septa and biglycan in airways in EP and a reduction of eNO synthase in airways in ET. In conclusion, both treatments with anti-IL-17 contributed to improve most of parameters evaluated in inflammation and extracellular matrix remodeling in this model of lung injury.eng
dc.description.sponsorshipCapesCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
dc.description.sponsorshipConselho Nacional de Desenvolvimento Cientifico and Tecnologico (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)
dc.description.sponsorshipHCFMUSP, Brazil
dc.relation.ispartofAmerican Journal of Physiology-Cell Physiology
dc.subjectairway remodelingeng
dc.subjectpancreatic elastaseeng
dc.subjectpulmonary emphysemaeng
dc.subject.othermatrix metalloproteinaseseng
dc.subject.otherinduced sputumeng
dc.titlePreventive and therapeutic effect of anti-IL-17 in an experimental model of elastase-induced lung injury in C57Bl6 miceeng
dc.rights.holderCopyright AMER PHYSIOLOGICAL SOCeng
dc.subject.wosCell Biologyeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng, Luciana R. C. R. B.:Univ Sao Paulo, Sch Med, Fac Med, Sao Paulo, SP, Brazil, Flavia C. R.:Univ Sao Paulo, Sch Med, Fac Med, Sao Paulo, SP, Brazil
hcfmusp.relation.referenceAlmeida-Reis R, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/8287125eng
hcfmusp.relation.referencePonce-Gallegos MA, 2017, INT J CHRONIC OBSTR, V12, P1857, DOI 10.2147/COPD.S136592eng
hcfmusp.relation.referenceAntus B, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2930434eng
hcfmusp.relation.referenceAristoteles LRCRB, 2013, BMC PULM MED, V13, DOI 10.1186/1471-2466-13-52eng
hcfmusp.relation.referenceBlack PN, 2008, EUR RESPIR J, V31, P998, DOI 10.1183/09031936.00017207eng
hcfmusp.relation.referenceCamargo LD, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01835eng
hcfmusp.relation.referenceChung KF, 2008, EUR RESPIR J, V31, P1334, DOI 10.1183/09031936.00018908eng
hcfmusp.relation.referenceCriner RN, 2019, COPD-J COPD FDN, V6, P64, DOI 10.15326/jcopdf.6.1.2018.0130eng
hcfmusp.relation.referencedos Santos TM, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01183eng
hcfmusp.relation.referenceEapen MS, 2017, RESPIROLOGY, V22, P1125, DOI 10.1111/resp.13021eng
hcfmusp.relation.referenceFujii U, 2016, AM J RESP CELL MOL, V55, P697, DOI 10.1165/rcmb.2016-0015OCeng
hcfmusp.relation.referenceGangemi S, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/164913eng
hcfmusp.relation.referenceGlobal Initiative for Chronic Obstructive Lung Disease (GOLD), 2018, EX SUMM GLOB STRATeng
hcfmusp.relation.referenceGosselink JV, 2010, AM J RESP CRIT CARE, V181, P1329, DOI 10.1164/rccm.200812-1902OCeng
hcfmusp.relation.referenceGroshong AM, 2014, ADV APPL MICROBIOL, V86, P41, DOI 10.1016/B978-0-12-800262-9.00002-0eng
hcfmusp.relation.referenceHsia CCW, 2010, AM J RESP CRIT CARE, V181, P394, DOI 10.1164/rccm.200809-1522STeng
hcfmusp.relation.referenceIsailovic N, 2015, J AUTOIMMUN, V60, P1, DOI 10.1016/j.jaut.2015.04.006eng
hcfmusp.relation.referenceIto JT, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209351eng
hcfmusp.relation.referenceJin Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111044eng
hcfmusp.relation.referenceKurimoto E, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-5eng
hcfmusp.relation.referenceKuwabara T, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/3908061eng
hcfmusp.relation.referenceLabaki WW, 2018, ANN AM THORAC SOC, V15, pS243, DOI 10.1513/AnnalsATS.201808-529MGeng
hcfmusp.relation.referenceLi YH, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/6587296eng
hcfmusp.relation.referenceLi YT, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-79eng
hcfmusp.relation.referenceLiu MY, 2019, ARCH ORAL BIOL, V103, P33, DOI 10.1016/j.archoralbio.2019.05.003eng
hcfmusp.relation.referenceLiu XD, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-66eng
hcfmusp.relation.referenceLoffek S, 2011, EUR RESPIR J, V38, P191, DOI 10.1183/09031936.00146510eng
hcfmusp.relation.referenceLopes FDTQS, 2013, HISTOL HISTOPATHOL, V28, P269, DOI 10.14670/HH-28.269eng
hcfmusp.relation.referenceLu XX, 2013, J HUAZHONG U SCI-MED, V33, P479, DOI 10.1007/s11596-013-1145-4eng
hcfmusp.relation.referenceMahadeva R, 2002, THORAX, V57, P908, DOI 10.1136/thorax.57.10.908eng
hcfmusp.relation.referenceMalerba M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/271918eng
hcfmusp.relation.referenceMARGRAF LR, 1991, AM REV RESPIR DIS, V143, P391eng
hcfmusp.relation.referenceMartins-Olivera BT, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/5346574eng
hcfmusp.relation.referenceMazur W, 2009, RESPIRATION, V78, P209, DOI 10.1159/000206010eng
hcfmusp.relation.referenceMontuschi P, 1999, EUR J PHARMACOL, V365, P59, DOI 10.1016/S0014-2999(98)00859-0eng
hcfmusp.relation.referencePeters M, 2016, AM J RESP CELL MOL, V54, P350, DOI 10.1165/rcmb.2014-0429OCeng
hcfmusp.relation.referencePossa SS, 2012, AM J PHYSIOL-LUNG C, V303, pL939, DOI 10.1152/ajplung.00034.2012eng
hcfmusp.relation.referenceRicciardolo FLM, 2005, J ALLERGY CLIN IMMUN, V116, P1028, DOI 10.1016/j.jaci.2005.06.034eng
hcfmusp.relation.referenceRicciardolo FLM, 2004, PHYSIOL REV, V84, P731, DOI 10.1152/physrev.00034.2003eng
hcfmusp.relation.referenceRighetti RF, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01021eng
hcfmusp.relation.referenceSchuliga M, 2015, BIOMOLECULES, V5, P1266, DOI 10.3390/biom5031266eng
hcfmusp.relation.referenceShapiro SD, 2003, EUR RESPIR J, V22, p30S, DOI 10.1183/09031936.03.00000903aeng
hcfmusp.relation.referenceShapiro SD, 2003, AM J PATHOL, V163, P2329, DOI 10.1016/S0002-9440(10)63589-4eng
hcfmusp.relation.referenceTakahashi A, 2014, AM J RESP CELL MOL, V51, P26, DOI 10.1165/rcmb.2013-0179OCeng
hcfmusp.relation.referenceTheodoro OA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020403eng
hcfmusp.relation.referencevan Straaten JFM, 1999, MODERN PATHOL, V12, P697eng
hcfmusp.relation.referenceVij N, 2018, AM J PHYSIOL-CELL PH, V314, pC73, DOI 10.1152/ajpcell.00110.2016eng
hcfmusp.relation.referenceVisse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3Deng
hcfmusp.relation.referenceVlahovic G, 1999, AM J RESP CRIT CARE, V160, P2086, DOI 10.1164/ajrccm.160.6.9706031eng
hcfmusp.relation.referenceWang AH, 2018, ARTIF CELL NANOMED B, V46, P783, DOI 10.1080/21691401.2017.1339051eng
hcfmusp.relation.referenceWang YJ, 2018, INT J CHRONIC OBSTR, V13, P3341, DOI 10.2147/COPD.S176122eng
hcfmusp.relation.referenceWeaver CT, 2013, ANNU REV PATHOL-MECH, V8, P477, DOI 10.1146/annurev-pathol-011110-130318eng
hcfmusp.relation.referenceWei JJ, 2015, INT J MOL MED, V36, P1384, DOI 10.3892/ijmm.2015.2353eng
hcfmusp.relation.referenceZhou XM, 2017, J THORAC DIS, V9, P3703, DOI 10.21037/jtd.2017.09.10eng
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM

Artigos e Materiais de Revistas Científicas - FM/MPT
Departamento de Patologia - FM/MPT

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/05
LIM/05 - Laboratório de Poluição Atmosférica Experimental

Artigos e Materiais de Revistas Científicas - LIM/20
LIM/20 - Laboratório de Terapêutica Experimental

Files in This Item:
File Description SizeFormat 
  Restricted Access
publishedVersion (English)1.94 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.